Evidence map›Paper›PMID 29847694›Full record

SynthesisBritish journal of clinical pharmacology2018

A multiple treatment comparison meta-analysis of monoamine oxidase type B inhibitors for Parkinson's disease.

C D Binde, I F Tvete, J Gåsemyr, B Natvig, M Klemp

Open access · bronzeAbstract readComparative StudyMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in British journal of clinical pharmacology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 9 pooled it
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 9 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Implications of dopaminergic medication withdrawal in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2022
    Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Review
  16. Article
  17. Article
  18. Chemical and Biological Evaluation of Novel 1International journal of molecular sciences · 2023
    Article
  19. Article
  20. Synthesis of Novel Benzo[Molecules (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

C D BindeDepartment of Pharmacology, University of Oslo, Oslo, Norway.
I F TveteNorwegian Computing Centre, Oslo, Norway.
J GåsemyrDepartment of Mathematics, University of Oslo, Oslo, Norway.
B NatvigDepartment of Mathematics, University of Oslo, Oslo, Norway.
M KlempDepartment of Pharmacology, University of Oslo, Oslo, Norway.ORCID 0000-0002-9530-8344
University of Oslo · NONorwegian Computing Center · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsTo the best of our knowledge, there are no systematic reviews or meta-analyses that compare rasagiline, selegiline and safinamide. Therefore, we aimed to perform a drug class review comparing all available monoamine oxidase type B (MAO-B) inhibitors in a multiple treatment comparison.

methodsWe performed a systematic literature search to identify randomized controlled trials assessing the efficacy of MAO-B inhibitors in patients with Parkinson's disease. MAO-B inhibitors were evaluated either as monotherapy or in combination with levodopa or dopamine agonists. Endpoints of interest were change in the Unified Parkinson's Disease Rating Scale (UPDRS) score and serious adverse events. We estimated the relative effect of each MAO-B inhibitor versus the comparator drug by creating three networks of direct and indirect comparisons. For each of the networks, we considered a joint model.

resultsThe systematic literature search and study selection process identified 27 publications eligible for our three network analyses. We found the relative effects of rasagiline, safinamide and selegiline treatment given alone and compared to placebo in a model without explanatory variables to be 1.560 (1.409, 1.734), 1.449 (0.873, 2.413) and 1.532 (1.337, 1.757) respectively. We also found all MAO-B inhibitors to be efficient when given together with levodopa. When ranking the MAO-B inhibitors given in combination with levodopa, selegiline was the most effective and rasagiline was the second best.

conclusionsAll of the included MAO-B inhibitors were effective compared to placebo when given as monotherapy. Combination therapy with MAO-B inhibitors and levodopa showed that all three MAO-B inhibitors were effective compared to placebo, but selegiline was the most effective drug.

Indexed as

Antiparkinson AgentsDrug Therapy, CombinationHumansLevodopaMonoamine Oxidase InhibitorsParkinson DiseaseRandomized Controlled Trials as TopicSelegilineTreatment OutcomeAntiparkinson AgentsLevodopaMonoamine Oxidase InhibitorsSelegilineMAO-B inhibitorsmultiple treatment comparisonParkinson's diseaserasagilinesafinamideselegiline

Identifiers

PMID29847694
PMCPMC6089809
OpenAlexW2805497424

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.